Chemical Communications · 2022 · 55 citations · 10 references
Life SciencesMolecular BiologyPharmacologyApoptosisDrug DiscoveryMolecular OncologyEnzymatic Cleavage StrategiesProtein DegradationProteolytic EnzymesProteasome InhibitorsProteasome SystemProteasome-mediated DegradationTargeted Protein DegradationUbiquitin-mediated DegradationUbiquitin-mediated ProteolysisUbiquitin-proteasome ProteolysisUbiquitin-proteasome Signaling
Targeting deubiquitinating enzymes (DUBs) has emerged as a promising therapeutic approach in several human cancers and other diseases. DUB inhibitors are exciting pharmacological tools but often exhibit limited cellular potency. Here we report PROTACs based on a ubiquitin-specific protease 7 (USP7) inhibitor scaffold to degrade USP7. By investigating several linker and E3 ligand types, including novel cereblon recruiters, we discovered a highly selective USP7 degrader tool compound that induced apoptosis of USP7-dependent cancer cells. This work represents one of the first DUB degraders and unlocks a new drug target class for protein degradation.
10
Molecular basis of USP7 inhibition by selective small-molecule inhibitors
A.P. Turnbull, Stephanos Ioannidis, Wojciech Krajewski et al. · Nature · 2017 · 468 citations
USP7 small-molecule inhibitors interfere with ubiquitin binding
Lorna Kategaya, Paola Di Lello, Lionel Rougé et al. · Nature · 2017 · 346 citations · Full text